Alberta Cancer Foundation announces new Breakthrough Fund recipient, driving commercial success of cancer research breakthroughs
31 mai 2024 12h00 HE
|
Alberta Cancer Foundation
Alberta Cancer Foundation announces new Breakthrough Fund recipient, driving commercial success of cancer research breakthroughs
Local startup Oncobiotix
Mountain America Credit Union’s Christine Ebert Recognized Among Utah Business 30 Women to Watch
31 mai 2024 10h00 HE
|
Mountain America Credit Union
SANDY, Utah, May 31, 2024 (GLOBE NEWSWIRE) -- Christine Ebert, vice president of project management at Mountain America Credit Union, was recently recognized by Utah Business as one of the 30 Women...
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
30 mai 2024 18h01 HE
|
Novartis Pharma AG
Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52)1Remibrutinib, an oral Bruton’s...
Incorta launches the first Operational GenAI with leading RAG and LLM providers
28 mai 2024 09h12 HE
|
Incorta, Inc.
FOSTER CITY, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Incorta, a leading operational lakehouse, today announces the launch of Operational GenAI, an unlimited and enterprise GenAI solution built on...
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
25 mai 2024 06h15 HE
|
Novartis Pharma AG
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction...
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
25 mai 2024 06h00 HE
|
Novartis Pharma AG
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical...
Gov. Holcomb Joins Lilly to Announce Additional $5.3 Billion Investment at LEAP District
24 mai 2024 09h34 HE
|
Indiana Economic Development Corporation
INDIANAPOLIS, May 24, 2024 (GLOBE NEWSWIRE) -- Today during the Indiana Global Economic Summit, Governor Eric J. Holcomb, chairman of the Indiana Economic Development Corporation, joined Eli Lilly...
Gov. Holcomb elevates Indiana to the world’s stage at Global Economic Summit
23 mai 2024 10h01 HE
|
Indiana Economic Development Corporation
INDIANAPOLIS, May 23, 2024 (GLOBE NEWSWIRE) -- Governor Eric J. Holcomb kicked off the second Indiana Global Economic Summit today, welcoming international delegations from more than 30 countries...
Gov. Holcomb elevates Indiana to the world’s stage at Global Economic Summit
23 mai 2024 09h54 HE
|
Indiana Economic Development Corporation
INDIANAPOLIS, May 23, 2024 (GLOBE NEWSWIRE) -- Governor Eric J. Holcomb kicked off the second Indiana Global Economic Summit today, welcoming international delegations from more than 30 countries...